No Chinese supply threat for drug companies, but scaling Great Wall is tough

“The concerns over supply of Chinese raw material proved to be ill-founded,” Nilesh Gupta, managing director of Lupin, told ET.

from Markets-Economic Times https://ift.tt/2AADj1c